Press release
Werum and Merck Serono Enter into Global MES Partnership
Hartmut Krome (right), Member of the Executive Board at Werum Software & Systems AG, with Dr. Hanns-Eberhard Erle, Senior Executive Vice President Technical Operations at Merck Serono while signing the contract.
Lueneburg, Germany, May 8, 2008 - Werum Software & Systems and Merck Serono just signed an agreement for the delivery of Manufacturing Execution Systems (MES). According to the Global MES Master Agreement, Merck Serono is planning to implement standardized MES solutions for both its pharmaceutical and biotechnological lines of production using Werum's MES products PAS-X PHARMA and PAS-X BIOTECH as a basis.
To start off, Merck Serono placed an order for two parallel MES projects. Werum will deploy PAS-X PHARMA at the Darmstadt (Germany) pharmaceutical site; simultaneously, Merck Serono will equip a new biotech plant in Vevey (Switzerland) with PAS-X BIOTECH. Once these two projects have been completed successfully, PAS-X will gradually be rolled out to other sites worldwide, starting with Semoy (France) and Mexico.
Consistent project procedures - especially for qualification and validation of the system - along with uniform production business processes at the sites are expected to bring Merck Serono three major benefits: They will reduce production risks, considerably shorten the time needed for documentation and result in a much faster release of manufacturing reports.
About Merck Serono
Merck Serono, the new division for innovative small molecules and biopharmaceuticals of Merck, was established following the acquisition of Serono and the integration of its business with the former Merck Ethicals Division. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, produces and commercializes innovative products to help patients with diseases with unmet needs.
For more information, go to::
www.merckserono.net or www.merck.de
Werum Software & Systems, Tel. USA +1 (973) 644-4000, Tel. Europe +49 (0)4131 8900-0, Press Contact: Volker Mensing, mensing@werum.com
Werum Software & Systems (www.werum.com) is a leading supplier of Manufacturing Execution Systems for the pharmaceutical and biopharmaceutical industry worldwide. Twelve of the world's top 20 pharmaceutical companies use Werum's product suite PAS-X to run their manufacturing business. Outstanding PAS-X features are the functions ensuring compliance and boosting performance. The modular system suite includes components for Production Planning and Scheduling, Master Batch Record Management, Electronic Batch Recording, Weighing and Dispensing, Material Flow Control and Tracking, Equipment Integration, Warehouse Management, Quality Management, and Performance Management based on KPI Analysis. Werum’s solutions and services range from software consulting, creation of functional specifications, and software development to turn-key delivery of integrated and validated Manufacturing Execution Systems. Founded in 1969, the IT company employs more than 290 people in its headquarters in Lueneburg, Northern Germany, the regional offices in West and Southwest Germany, and the subsidiary in Parsippany, New Jersey, USA.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Werum and Merck Serono Enter into Global MES Partnership here
News-ID: 44099 • Views: …
More Releases from Werum Software & Systems
13th PAS-X User Group Meeting in Germany
13th PAS-X User Group Meeting in Germany
Werum Manufacturing IT Conference with record attendance
Lueneburg, Germany, 26 October 2011 – The 13th international PAS-X User Group Meeting took place from 13 to 14 October 2011 in Lueneburg, Germany, with a record attendance. On the invitation of Werum Software & Systems AG, almost 200 pharmaceuticals experts from approximately 20 countries exchanged their thoughts and ideas on the use of the PAS-X production management…
Indian pharmaceutical major Dr. Reddy's chooses to implement Werum's MES
Dr. Reddy's Laboratories Ltd. deploys PAS-X at Hyderabad site
Lueneburg, Germany, August 20, 2010 – Dr. Reddy's Laboratories Ltd. has decided to introduce PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, at its site in Bachupally, Hyderabad.
Dr. Reddy's plans to optimize the efficiency, quality, compliance and performance of its production processes with PAS-X. Werum is the leading supplier of MES systems for the pharmaceutical and biopharmaceutical industries…
MSD Packaging Lines run with PAS-X
Lueneburg, Germany, August 17, 2010 - MSD deployed PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, to run its packaging line operations in Heist-op-den-Berg, Belgium in order to increase the compliance level during packaging operations and subsequently shorten lead times to improve delivery performance. Operations include fully automated blister lines and filling lines, semi-automated packaging lines and manual packaging processes. The project for introducing PAS-X was completed…
Successful rollout of PAS-X MES Weighing & Dispensing at AstraZeneca in India an …
Manufacturing Execution System projects completed successfully
Lueneburg, Germany, March 25, 2010 - Manufacturing Execution System (MES) software provider Werum Software & Systems has successfully finalized the installation of PAS-X MES in AstraZeneca's Wuxi site in the Jiangsu Province, China. This first-time MES project in the Chinese pharmaceutical industry follows an employment of Werum's PAS-X MES software in AstraZeneca's Indian production site in Bengaluru (formerly Bangalore) in 2009.
Both MES projects are part…
More Releases for Merck
Swine Fever Vaccine Market Detailed in New Research Report By 2032 | Merck & Co. …
🚀 𝐒𝐰𝐢𝐧𝐞 𝐅𝐞𝐯𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟗% (𝟐𝟎𝟐𝟓 - 𝟐𝟎𝟑𝟐)
The Swine Fever Vaccine Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
» 70% efforts of Primary Research
» 15% efforts of Secondary Research
» 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited companies
📈…
Women's Health Market Industry Growth Report to 2031 Merck KGaA, Merck & Co, Fer …
[New York, December 2024] Women's Health encompasses a broad spectrum of medical and wellness services tailored to address the unique health needs of women across all life stages. This crucial sub-market of healthcare highlights the necessity for specialized treatments, preventive care, and holistic wellness approaches that resonate with today's female patients. Women's Health isn't just a niche sector; it represents a burgeoning field within healthcare, mirrored by an increasing global…
Laboratory Syringe Market Size, Growing Demand to 2036 GESERCO, Merck Millipore, …
A laboratory syringe is a precise instrument commonly used for the accurate measurement and transfer of liquids or gases in scientific experiments. Unlike standard medical syringes, laboratory syringes are often made of materials such as glass or high-quality plastic to withstand chemical reactions and offer greater clarity for observing contents. They come in a range of sizes, from as small as 1 mL to over 100 mL, and are often…
Leuprorelin Acetate Market Analysis By Top Keyplayers - Merck, Takeda, MediGene, …
The "Leuprorelin Acetate Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Leuprorelin Acetate Market, 2024-2031
Verified Market Research's most recent report, "Leuprorelin Acetate Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth…
Avelumab Market Analysis By Top Key Players - Merck, Pfizer, Merck
The "Avelumab Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Avelumab Market, 2024-2031
Verified Market Research's most recent report, "Avelumab Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the…
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co …
𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI.
The Nanobodies market report analyse the manufacturing cost of the…
